Emerging roles for long non-coding RNA in myeloid cell responses to glucocorticoids
| PhD Student | University of Glasgow Supervisor | Astra Zeneca Supervisor |
| Heather Mackie | Professor Rose Maciewicz |
Dr Carl Goodyear
Director, GLAZgo Discovery Centre
Senior Lecturer, Institute of Infection, Immunity and Inflammation
University of Glasgow
Dr Carl Goodyear studied at the University of Glasgow and Glasgow Caledonian University, gaining a BSc with honours in Molecular Biology in 1996 and a PhD in Molecular Immunology in 1999. Upon completing his PhD, Dr Goodyear moved to the US and worked in the Department of Medicine at the University of California at San Diego where he held the position of Assistant Professor. During this period Dr Goodyear was awarded a Cancer Research Institute Postdoctoral Fellowship, became a National Blood Foundation Scholar, and received a number of awards including the National Blood Foundation David B. Pall Prize for Innovative Research in Transfusion Medicine and an Arthritis Foundation Investigator Award. In 2006 he returned to work in the UK at the Institute of Infection Immunity and Inflammation in the University of Glasgow. He was awarded a prestigious Arthritis Research UK Fellowship and shortly after became a Senior Lecturer. Dr Goodyear’s research has continued to gain awards such as the Inaugural Medical Research Scotland Vipiana Award.
Dr Goodyear’s research group is currently focused on understanding immunopathogenesis of disease (i.e., Rheumatoid Arthritis, Osteoarthritis & Multiple Myeloma) and translating this knowledge into viable therapeutic agents for patients. In parallel, Dr. Goodyear also leads a Translational Immunology programme, which provides the critical interface between clinical and basic science.
Professor Rose Maciewicz
Chief Scientist (Honorary Professor University of Manchester)
Respiratory, Inflammation, Autoimmunity Abed, AstraZeneca, Cambridge
Rose Maciewicz studied at the University of Buffalo graduating with a BA in Biology (Summa Cum Laude) in 1976, and a MA (1978) / PhD (1980) in Cell and Molecular Biology. Upon completing her PhD, on in vivo hormonal induced gene activation, she undertook a Post Doctoral Research Associate position at The Johns Hopkins University, Department of Biology, Baltimore, Maryland where she investigated the structure-function relationship of gene activation at the nucleosomal level. Moving to the UK she did further postdoctoral work on cysteine and metalloproteinases in disease which was funded by the Arthritis Research Council as well as collaborated on projects funded by the Cancer Research UK. She undertook a sabbatical as a group leader at a biotech company (Prototek) in California before she joined AstraZeneca (legacy companies ICI, Zeneca). At AstraZeneca she has held various leadership positions (science, project and management). She has in-depth experience in research and early development across a broad range of diseases including musculo-skeletal, cardiovascular and respiratory diseases. Projects she initiated in the osteoarthritis area are currently in early clinical development. Externally she has been an committee members for taskforces / steering groups that have set the future agenda in osteoarthritis, as well as private public partnerships in regenerative medicine (Regener8) and stem cells in drug discovery (SC4SM). She has been an external advisor for orthopeadic companies. A previous committee member and Secretary of the British Society for Matrix Biology, she currently sits on the Scientific Advisory Board for Arthritis UK Pain Centre, the Board of Directors for the Manchester Collaborative Centre for Inflammation Research (MCCIR) and the White Rose University Centre doctoral training program funded by the BBSRC. She has established and leads a highly-regarded internal postdoctoral programme in AstraZeneca that currently supports 100 post-docs. She has organised major external conferences (Lund COPD Symposium). She collaborates widely with the external academic community and has published extensively.